Latest Breaking News On - Soheil meshinchi - Page 1 : comparemela.com

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with .

United statesSan diegoSouth san franciscoLuveltamab tazevibulinSoheil meshinchiSutro biopharmaEmily whiteGlobenewswire incExchange commissionAmerican society of hematology annual meetingDrug administrationSutro biopharma incHematology annual meetingAbout luveltamabFast trackOvarian cancer

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South san franciscoUnited statesSan diegoNew yorkCity ofUnited kingdomContactemily whitesutro biopharmaSoheil meshinchiPiper sandlerHans peter gerberExchange commission onCompany quarterly report on formCompany annual report on formEuropean society for medical oncologyBlackstone life sciencesExchange commission

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

- Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-G.

South san franciscoUnited statesSan diegoCity ofUnited kingdomNew yorkEmily whiteHans peter gerberSutro biopharmaSoheil meshinchiPiper sandlerExchange commissionAmerican society of hematology annual meetingAdditional pipeline developmentEuropean society for medical oncologyBlackstone life sciences

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSutro biopharmaBionova pharmaLuveltamab tazevibulinSoheil meshinchiAlpha folCompany quarterly report on formSutro biopharma incEuropean society for medical oncologyAmerican society of clinical oncologyInternational nonproprietary nameAdditional pipeline developmentAmerican association for cancer researchCompany annual report on formExchange commission onBlackstone life sciences

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

10.08.2023 - - Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients .

United statesAnniej changBionova pharmaLuveltamab tazevibulinSutro biopharmaSoheil meshinchiAlpha folEuropean society for medical oncologyInternational nonproprietary nameCompany quarterly report on formAmerican society of clinical oncologySutro biopharma incExchange commissionExchange commission onCompany annual report on formAmerican society of hematology annual meeting